Precedent Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Precedent Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$242K	Buy	+463	New	+$237K	0.04%	187

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Precedent Wealth Partners's VRTX Position: Q3 2026 in Review

Precedent Wealth Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 463 shares worth $242K. The stake represents 0.04% of the portfolio and ranks #187 among its holdings.

1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Precedent Wealth Partners held 463 shares of Vertex Pharmaceuticals worth $242K as of Q3 2026.
Vertex Pharmaceuticals was a new Precedent Wealth Partners position in Q3 2026.
Vertex Pharmaceuticals made up 0.04% of Precedent Wealth Partners's portfolio in Q3 2026, its #187 holding.
1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Precedent Wealth Partners's 13F filing for Q3 2026, filed 21 Oct 2026.